Loading...
XASX
IMR
Market cap340mUSD
Oct 30, Last price  
1.35AUD
1D
3.85%
1Q
-27.42%
IPO
9.76%
Name

Imricor Medical Systems Inc

Chart & performance

D1W1MN
XASX:IMR chart
P/E
—
P/S
1,125.81
EPS
—
Vol. 1Y
53.75%
Shs. 5Y
22.11%
Rev. 5Y
-15.50%
Div Yld LY
—
Div Yld TTM
—
Revenues
303k
-68.47%
703,919565,5971,342,573639,704702,161696,267816,011615,568959,424302,502
Net income
-26m
L-11.76%
-5,494,861-6,710,723-7,297,118-14,798,147-13,076,801-20,556,113-17,534,184-22,625,902-29,692,831-26,201,489
CFO
-20m
L+26.79%
-4,051,414-5,647,803-6,340,013-6,627,993-12,230,689-17,488,546-16,510,221-12,977,456-15,573,910-19,746,569

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States, Europe, and the Middle East. The company’s products include Vision-MR Ablation Catheter 2.0, a MR-compatible cardiac ablation catheter; Vision-MR Diagnostic Catheter, a MR-compatible diagnostic catheter; NorthStar mapping system, a real-time, high-resolution soft tissue imaging of MRI to guide and visualize procedures with exceptional clarity; and Advantage-MR EP Recorder / Stimulator. It also offers Vision-MR Dispersive Electrode to minimize eddy currents induced on the device’s conductive pads during mr scanning. Imricor Medical Systems, Inc. was incorporated in 2006 and is headquartered in Burnsville, Minnesota.

Key people

Steve Wedan
Executive Chairman of the Board, President, Chief Executive Officer · since 2006
Mark Tibbles
Non-Executive Lead Independent Deputy Chairman of the Board · since 2014
Jonathon Gut
Chief Financial Officer, Vice President - Finance · since 2022
Gregg Stenzel
Chief Operating Officer · since 2021
Vic Fabano
Vice President - Operations · since 2022
Nick Corkill
Vice President - Corporate Strategy · since 2024
Dan Sunnarborg
Vice President - Engineering · since 2007
Jennifer Weisz
Vice President - Regulatory and Quality · since 2018
Greg Englehardt
Executive Director of Sales · since 2018
Nick Twohy
Vice President of Marketing · since 2019
Kate Lindborg
Director of Clinical Affairs · since 2022
Kobe Li
Company Secretary · since 2019
Jeffrey Leighton
Director · since 2024
Peter Mcgregor
Non-Executive Director · since 2019
Non-Executive Independent Director · since 2025
Anita Messal
Non-Executive Independent Director · since 2021
IPO date
Aug 30, 2019
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT